MATN - Mateon Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.2000
+0.0090 (+4.71%)
At close: 3:19PM EDT
Stock chart is not supported by your current browser
Previous Close0.1910
Open0.1910
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1910 - 0.2000
52 Week Range0.0500 - 0.3100
Volume24,225
Avg. Volume85,266
Market Cap16.42M
Beta (3Y Monthly)3.39
PE Ratio (TTM)N/A
EPS (TTM)-0.0730
Earnings DateApr 11, 2019 - Apr 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.55
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Mateon Reports First Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan.

  • GlobeNewswire25 days ago

    Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline

    Mateon Therapeutics, Inc. (MATN) and Oncotelic Inc. announced today that they have completed their previously announced merger. The combined company has a focused pipeline of TGF-β RNA Therapeutics for late stage cancers, including gliomas, pancreatic cancer and melanoma.

  • GlobeNewswirelast month

    Mateon Enters into Merger Agreement with Oncotelic

    Mateon Therapeutics, Inc. (MATN) and Oncotelic Inc., a privately-held, late clinical-stage cancer immunotherapy company, announced today that they have entered into a definitive agreement with respect to a merger, creating a publicly traded immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. “We believe that the merger of Oncotelic and Mateon will create a combined company that can generate shareholder value through a promising pipeline of next generation immunotherapies targeting several significant cancer markets where there is a paucity of therapeutic options and lack of an effective immunotherapy protocol,” said Vuong Trieu, Ph.D., Co-Founder, Chairman and Chief Executive Officer of Oncotelic.

  • GlobeNewswire6 months ago

    Mateon Therapeutics Reports Third Quarter 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan.

  • ACCESSWIRE7 months ago

    Stonegate Capital Partners Initiates Coverage on Mateon Therapeutics, Inc.

    Mateon Therapeutics, Inc. (Mateon) is a clinical stage biopharmaceutical company that develops small molecule injectable drugs for the treatment of cancer patients, specifically targeting orphan indications. The Company is currently focused on advancing two programs, CA4P as an immuno-oncology agent for advanced metastatic melanoma and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and related myelodysplastic syndromes (MDS), with the ultimate goal of selling rights to a larger pharma player following additional clinical data.